US indicts Chinese firms over fentanyl crypto payment networks and stablecoins

The US indicted two Chinese pharmaceutical companies and six individuals in Ohio, alleging they supplied fentanyl precursor chemicals and instructed traffickers to pay via fentanyl crypto payment networks. Prosecutors also highlighted “cutting agents” that can boost fentanyl yield, naming medetomidine as a key substance. Authorities say customers were directed to send funds to wallets controlled by the defendants, with proceeds routed through an overseas settlement path. The DOJ described a “layering” flow: stablecoins moved to a collection address, were split across pass-through wallets, and were converted to fiat at a cross-border “exit point.” The case was filed under the FBI’s Operation Box Cutter and also includes allegations related to supporting a Mexico cartel designated as a foreign terrorist organization. If convicted, defendants could face life sentences plus added money-laundering and terrorism-related charges. Separately, TRM Labs reported that about 97% of China-based drug precursor manufacturers accept crypto payments. It estimated on-chain inflows to these vendors were $39.1M in 2025 versus $34.7M in 2024 and $30.9M in 2023. For crypto traders, this is a compliance-focused warning: fentanyl crypto payment networks—often using stablecoins—remain a law-enforcement priority. Short-term risk is sentiment pressure on stablecoin usage and exchange/KYC-AML scrutiny, while longer-term effects could include tighter controls on payment rails and digital-asset service providers.